tbuckley/cabot-search huggingface dataset:
Nonsurgical treatments for stage 0-IA squamous esophageal cancer.
Authors: Hitoshi Ito, Satoshi Itasaka, Shinichi Miyamoto, Yasumasa Ezoe, Manabu Muto, Eiji Tanaka, Yoshiharu Sakai, Tsutomu Chiba, Masahiro Hiraoka
Journal: Journal of Clinical Oncology (2012)

113 Background: Surgery has been the standard treatment for operable squamous esophageal cancer. However, radiation therapy/chemoradiotherapy (RT/CRT) or endoscopic resection (ER) could be an alternative treatment option for stage 0-IA (TNM 7th edition) squamous esophageal cancer, because these treatments are less invasive and can preserve the organ. To evaluate the efficacy of surgery, RT/CRT and EC for stage 0-1A squamous esophageal cancer in clinical practice, we reviewed our experience. Methods: From March 2007 to December 2010, 92 patients with stage 0-IA squamous esophageal cancer were treated in our institute. Overall survival, relapse-free survival, and relapse pattern were evaluated according to the initial treatment modality. Results: Of 92 patients (pts), 76 were male and 16 were women. Median age was 65.5 years old. Tis/T1a/T1b:4/36/52. Median follow up time was 29.1(4.7-55.5) months. As an initial treatment, 9 pts received surgery, 27 pts received RT/CRT and 56 pts received ER. Among the pts underwent ER, one patient underwent esophagectomy and 13 pts were received CRT based on the pathological evaluation for the risk of the lymph node metastasis. Two-year relapse free survival and overall survival of surgery, RT/CRT and ER was 77.8%/100%, 68.6%/100% and 89.8%/95.7%, respectively. After completion of initial therapy, local failures (residual or recurrent disease), regional lymph node relapse and distant metastasis and 1 undetermined relapse were observed in 6, 3 and 5 pts, respectively. Eight out of the 15 pts with recurrence could be disease free after salvage therapy. While 4 pts died during the follow up period, all pts died from other diseases and no pts died from esophageal cancer. Overall esophageal preservation rate was 89.1% (82/92). Conclusions: Although longer follow-up was needed, this study showed that non-surgical treatments (RT/CRT or ER) for stage 0-1A squamous esophageal cancer could be an alternative treatment option and could provide a chance of organ preservation. [Table: see text]
Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.
Authors: Monique Terwijn, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Willemijn Scholten, Sonja Zweegman, Gert Ossenkoppele, Gerrit Jan Schuurhuis
Journal: Blood (2009)
Myeloablative Timed Sequential Busulfan Is Safe in Older Patients
Authors: Uday R. Popat, Patricia S Fox, Roland Bassett, Julianne Chen, Benigno C. Valdez, Jitesh Kawedia, Sairah Ahmed, Amin M. Alousi, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Roy Jones, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Amanda Olson, Betul Oran, Simrit Parmar, Muzaffar H. Qazilbash, Nina Shah, Elizabeth J Shpall, Borje S Andersson, Richard E. Champlin
Journal: Blood (2014)
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.
Authors: Marcos De Lima, Leandro de Padua Silva, Sergio Giralt, Krishna Komanduri, Borje S. Andersson, Chitra Hosing, Muzaffar Qazilbash, Elizabeth Shpall, Peter Thall, Weiqing Zhang, Gloria McCormick, Xuemei Wang, Uday Popat, Andres Soriano, Amin Alousi, Richard Champlin, Guillermo Garcia-Manero
Journal: Blood (2008)
A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
Authors: Suzanne Lentzsch, Amy O’Sullivan, Silvana Lalo, Carrie Kruppa, Diane Gardner, Ryan C Kennedy, Steve Burt, Markus Y Mapara, Robert Redner, David Roodman, Robert L Volkin, Jeffrey Zonder
Journal: Blood (2009)
UK lung cancer care must improve drastically, says report
Authors: Jacqui Wise
Journal: BMJ (2016)

Lung cancer specialists and charities have set out a strategy to raise the United Kingdom’s five year lung cancer survival rates to 25% by 2025.1

The UK Lung Cancer Coalition’s report, 25 by 25: a Ten Year Strategy to Improve Lung Cancer Survival Rates , calls for a dramatic improvement in lung cancer care to improve UK survival rates and prevent over 11 000 deaths a year. It says that UK governments must prioritise improving lung cancer survival and set up a UK-wide task force in …
Skeletal muscle derived stem cells microintegrated into a biodegradable elastomer for reconstruction of the abdominal wall
Authors: Keisuke Takanari, Ryotaro Hashizume, Yi Hong, Nicholas J. Amoroso, Tomo Yoshizumi, Burhan Gharaibeh, Osamu Yoshida, Kazuhiro Nonaka, Hideyoshi Sato, Johnny Huard, William R. Wagner
Journal: Biomaterials (2016)
Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function
Authors: Cecilia K. Andersson, Alexandra Adams, Prasad Nagakumar, Cara Bossley, Atul Gupta, Daphne De Vries, Afiqah Adnan, Andrew Bush, Sejal Saglani, Clare M. Lloyd
Journal: Journal of Allergy and Clinical Immunology (2016)

Neutrophils and IL-17A have been linked mechanistically in models of allergic airways disease and have been associated with asthma severity. However, their role in pediatric asthma is unknown.We sought to investigate the role of neutrophils and the IL-17A pathway in mediating pediatric severe therapy-resistant asthma (STRA).Children with STRA (n = 51; age, 12.6 years; range, 6-16.3 years) and controls without asthma (n = 15; age, 4.75 years; range, 1.6-16 years) underwent clinically indicated fiberoptic bronchoscopy, bronchoalveolar lavage (BAL), endobronchial brushings, and biopsy. Neutrophils, IL-17A, and IL-17RA-expressing cells and levels of IL-17A and IL-22 were quantified in BAL and biopsies and related to clinical features. Primary bronchial epithelial cells were stimulated with IL-17A and/or IL-22, with and without budesonide.Children with STRA had increased intraepithelial neutrophils, which positively correlated with FEV1 %predicted (r = 0.43; P = .008). Neutrophilhigh patients also had better symptom control, despite lower dose maintenance inhaled steroids. Submucosal neutrophils were not increased in children with STRA. Submucosal and epithelial IL-17A-positive cells and BAL IL-17A and IL-22 levels were similar in children with STRA and controls. However, there were significantly more IL-17RA-positive cells in the submucosa and epithelium in children with STRA compared with controls (P = .001). Stimulation of primary bronchial epithelial cells with IL-17A enhanced mRNA expression of IL-17RA and increased release of IL-8, even in the presence of budesonide.A proportion of children with STRA exhibit increased intraepithelial airway neutrophilia that correlated with better lung function. STRA was also characterized by increased airway IL-17RA expression. These data suggest a potential beneficial rather than adverse role for neutrophils in pediatric severe asthma pathophysiology.
Breast cancer risk perception in a high-risk population
Authors: M. E. Rader, J. Chun, A. Abraido-Lanza, A. Komorowski, J. S. Anker, F. Schnabel
Journal: Journal of Clinical Oncology (2008)

1542 Background: Women's perceptions of breast cancer risk and how they assess the value of prevention strategies are likely to determine their interest in preventive interventions and trials. The objectives of this study were to assess the effectiveness of an educational intervention on women's perception of breast cancer risk, understand their perceptions on the effectiveness of risk reduction interventions and assess which level of risk reduction would justify their participation in chemoprevention trials. Methods: An educational seminar on breast cancer risk was conducted. Questionnaires were administered before and after the educational intervention. These pre- and post-questionnaires provided data to calculate Gail risk scores and assess risk perception. The IRB of Nyack Hospital approved this study. Paired data analyses using Mantel-Haenszel odds ratios were conducted with statistical significance at p-value <0.05. Results: While 65 women completed both questionnaires, the total study population was restricted to the 38 participants who had no prior history of breast cancer and who provided information to compute a Gail score. Median age was 56 years (range: 28–72). 12 out of 38 (32%) women had a strong family history of breast cancer. The mean Gail score was 2.2. 17 out of 38 (45%) women had Gail scores ≥1.7%. 34% of the participants overestimated the average woman's lifetime risk of developing breast cancer. This perception decreased significantly to 8% after the educational intervention. Most women rated diet as the “most effective” risk reduction intervention, followed by physical activity. A majority of the participants (53%) said they would be willing to consider participating in chemoprevention trials if they promised a risk reduction of at least 35%. Conclusions: The results of this study demonstrate that educational efforts can reduce inaccuracies in women's perception of breast cancer risk. Participants expressed marked interest in participating in potential risk reduction interventions including vitamins, diet, and chemoprevention trials. Participants indicated that a potential risk reduction of 35% would be required for them to consider a chemoprevention trial. No significant financial relationships to disclose.
Clinicopathological analysis of bone tumors with unknown primary site in adults.
Authors: T. Azuma
Journal: Journal of Clinical Oncology (2010)

e20525 Background: Bone is a frequent metastatic site in malignancy as well as brain, lung and liver. If the diagnosis of malignancy is not determined by any other method, bone biopsy of the involved lesion will be performed to make a diagnosis of malignancy and indicate its primary site. Objective: To pathologically classify bone tumors with unknown primary site. Design: Case-series study. Setting: Single institute patients: 1. Diagnosed as having a malignancy by bone biopsy during the past 10 years because of undetermined malignancy and unknown primary site. 2. More than 16 years old. 3. Patients who had suffered from malignancy in the past were excluded. 4. Patients with diffuse bone marrow invasion were also excluded. Methods: We reviewed clinical information from each medical record including age, sex, and biopsy site and classified according to pathological diagnosis. Primary outcome: Pathological diagnosis. Results: Among 89 patients receiving bone biopsy in the past decade, 27 patients (male 15pts, female 12pts) were eligible. Median age was 60 (± 13.1) years. Biopsy sites were as follows; lumbar vertebra in 5pts, thoracic and sacral vertebra in 4pts, iliac bone in 3pts, and pubic bone in 2pts, and others in 9pts, respectively. According to pathological diagnosis, 14 patients had a carcinoma (adenocarcinoma in 4pts, squamous cell carcinoma and small cell carcinoma in 1pt, carcinoma with not otherwise specified type in 8pts, respectively). Ten patients had a hematologic malignancy, consisting of 5pts of diffuse large B-cell lymphoma, 2pts of plasma cell neoplasm, 1pt of B-lymphoblastic lymphoma, 1pt of B-cell non-Hodgkin lymphoma, and 1pt of granulocytic sarcoma, respectively. The pathological diagnosis of the rest three patients were unclassifiable sarcoma, mesenchymal tumor and malignant tumor in each patient. Conclusions: Hematologic malignancy occupied in about 40% of bone tumor with unknown primary site. As hematologic malignancy is usually highly sensitive to chemotherapy, bone biopsy should be considered if primary site is unknown in suspected malignancy with bone lesion. No significant financial relationships to disclose.
A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.
Authors: S. Kummar, A. P. Chen, J. J. Ji, D. Allen, M. J. Egorin, D. R. Gandara, H. Lenz, R. Morgan, E. M. Newman, J. H. Doroshow
Journal: Journal of Clinical Oncology (2010)

2605 Background: Inhibition of poly (ADP-ribose) (PAR) polymerase (PARP) is expected to enhance the DNA-damaging effects of chemotherapy. PARP has also been implicated in endothelial cell migration. A is an orally available, potent inhibitor of PARP-1 and PARP-2. C is an alkylator that has effects on thrombospondin 1, endothelial cells and T reg cells. Methods: Objectives were to establish the safety, tolerability, and MTD of the combination of A with metronomic C; determine the PK of A; and evaluate PARP inhibition in PBMCs and tumor samples. Patients (pts) had histologically documented solid tumors and lymphoid malignancies that had progressed following standard therapy; ≥ 18 years old; KPS > 70%; adequate bone marrow, hepatic and renal function. Cycle length was 21 d. DLT was defined as drug-related gr ≥ 3 nonhematologic or gr 4 hematologic toxicities during cycle 1. PBMCs and optional tumor biopsies were collected, and PAR levels were determined using a validated ELISA. Results: Eighteen pts have been enrolled in 6 DLs. Median age 56 (range 38-74 years); diagnosis (# of pts): NHL (2), sarcoma (1), ovarian (5, 3 known BRCA2+), breast (6, 3 triple-negative breast cancer [TNBC], 1 known BRCA2+), pancreatic (1), carcinoid (1), colon (1), melanoma (1). Drug-related toxicities have been: gr 3/4 lymphopenia (3 pts) and gr 2 neutropenia (2 pts). Confirmed PRs were observed in 3 pts: 2 BRCA+ ovarian cancer; 1 TNBC. One pt with low-grade lymphoma has a minor response with >30% reduction in target lesions. Stable disease in 2 pts: BRCA2+ male breast cancer for 8 cycles; BRCA+ ovarian cancer for 12 cycles. At least 50% reduction in PAR levels in PBMCs was observed in 16 of the 18 pts. Greater than 95% reduction in PAR levels was observed in paired tumor biopsies from 2 pts (DL 1, DL 6). Conclusions: This oral regimen of A with metronomic C is well tolerated, has shown activity in BRCA+ ovarian cancer and TNBC, and should be evaluated in phase II trials. Accrual is continuing to the highest proposed DL to establish the recommended phase II dose. Funded by NCI Contract No. HHSN261200800001E. Dose level (DL) A po qd C po qd 1 20 mg × 7 d 50 mg 2 30 mg × 7 d 50 mg 3 30 mg × 14 d 50 mg 4 40 mg × 21 d 50 mg 5 40 mg × 21 d 100 mg 6 50 mg × 21 d 50 mg 7 60 mg × 21 d 50 mg Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Abbott Laboratories Abbott Laboratories, Bristol-Myers Squibb
Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication
Authors: Erika Tissino, Chiara Caldana, Dania Benedetti, Francesca Rossi, Michele Dal Bo, Pietro Bulian, Riccardo Bomben, Francesco Zaja, Annalisa Chiarenza, Tanja Nicole Hartmann, Alexandre Chigaev, Giovanni Del Poeta, Valter Gattei, Antonella Zucchetto
Journal: Blood (2015)
Clusters of ineffective efforts during mechanical ventilation: impact on outcome
Authors: Katerina Vaporidi, Dimitris Babalis, Achilleas Chytas, Emmanuel Lilitsis, Eumorfia Kondili, Vasilis Amargianitakis, Ioanna Chouvarda, Nicos Maglaveras, Dimitris Georgopoulos
Journal: Intensive Care Medicine (2016)
Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination
Authors: Jesus G Berdeja, Sikander Ailawadhi, Ruben Niesvizky, Jeffrey L Wolf, Sybil H Zildjian, James O'Leary, Asher Chanan-Khan
Journal: Blood (2010)
On the effectiveness of multilevel selection
Authors: Charles J Goodnight
Journal: Behavioral and Brain Sciences (2016)

Abstract Experimental studies of group selection show that higher levels of selection act on indirect genetic effects, making the response to group and community selection qualitatively different from that of individual selection. This suggests that multilevel selection plays a key role in the evolution of supersocial societies. Experiments showing the effectiveness of community selection indicate that we should consider the possibility that selection among communities may be important in the evolution of supersocial species.
GW26-e2948 The Application of Intravascular Ultrasound to Evaluate Pulmonary Vascular Properties and Predict Mortality in Pulmonary Arterial Hypertension
Authors: Zongye Cai, Jun Pu, Ling-yue Sun, Cheng-de Yang, Ben He, Jieyan Shen
Journal: Journal of the American College of Cardiology (2015)
Flow Cytometric Analysis of Donor-Recipient Chimerism Using Anti-HLA Antibody after HLA-Mismatched Cord Blood Transplantation.
Authors: Satoshi Takahashi, Nobukazu Watanabe, Misako Iezaki, Takashi Shibata, Jun Ooi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Takeshi Kobayashi, Aki Sato, Seiko Kato, Hiromitsu Nakauchi
Journal: Blood (2007)
Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer.
Authors: Niall C. Tebbutt, Timothy Jay Price, Katrin Marie Sjoquist, Anne-Sophie Veillard, Merryn Hall, Danielle Angela Ferraro, Nicole Wong, Nick Pavlakis, Andrew Strickland, Suresh Chandra Varma, Prasad Cooray, Rosemary Young, Craig Underhill, Jennifer Anne Shannon, Vinod Ganju, Val Gebski
Journal: Journal of Clinical Oncology (2013)

4081 Background: This randomized phase II study evaluated the efficacy and safety of P, a fully human mAb against the epidermal growth factor receptor combined with T-based chemotherapy in advanced OG cancer. Methods: Eligible pts had histologically confirmed metastatic OG cancer (adeno-carcinoma and squamous cell carcinoma) were ≥18 years of age, PS 0-2, with adequate renal, haematologic and liver function with measurable disease. All pts provided informed consent. Selection was not based on kras determination. Pts received T 30mg/m 2 d1,8, C 60mg/m 2 d1 and F; investigator choice of 5FU infusion 160mg/m 2 /d or capecitabine 500mg/m 2 bd continuous ±P 9 mg/kg d1 q3w. Treatment was administered for 8 cycles or until PD. The primary endpoint was response rate according to RECIST (1.1) assessed q6w. Planned enrolment target was 100 pts. Stratification variables included histology, PS and choice of F. Results: From April 2010 to November 2011, 77 pts were enrolled from 15 institutions. A safety alert from the REAL3 study (also involving P in OG cancer) prompted an unplanned review of data from ATTAX3 by the IDMC. The IDMC found no evidence of adverse outcomes associated with P, but as it did not appear that P would significantly improve efficacy, they recommended cessation of the study to new enrolment. Previously enrolled pts were treated and followed according to protocol. Median follow up is 24m. Treatment arms were well balanced; median age 59, 64y, male 77%, 87%, PS0-1 95%,90%, adenocarcinoma 90%,90%, capecitabine 67%, 66% for TCF/TCF-P, respectively. Common grade 3/4 toxicities include infection 18%,24%, febrile neutropenia 10%, 5%, anorexia 10%, 24%, nausea 18%,30%, stomatitis 3%,5%, diarrhoea 15%,24% , acneiform rash 0%, 8%, fatigue 18%, 30%, hypomagnesemia 10%, 16% for TCF/TCF-P. Efficacy outcomes are summarized in Table. Conclusions: The addition of P to T-based chemotherapy in advanced OG cancer did not improve efficacy and was associated with an increase in some toxicities. Clinical trial information: ACTRN12609000109202. [Table: see text]
Alloreactive Alleles for the IL-10 -1064 Polymorphism in the Donor Associate with Chronic GVHD, in a Chimerism Mediated Fashion, after HLA Identical Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Cintia Manzano, Noemi Sanchez-Hernandez, Diana Barroso, Pascual Balsalobre, Milagros Gonzalez-Rivera, David Serrano, Rafael Carrion, Alfonso Gomez-Pineda, Jose L. Diez-Martin, Ismael Buño
Journal: Blood (2006)
Coronary Atherosclerosis T1-Weighed Characterization With Integrated Anatomical Reference
Authors: Yibin Xie, Young-Jin Kim, Jianing Pang, Jung-Sun Kim, Qi Yang, Janet Wei, Christopher T. Nguyen, Zixin Deng, Byoung Wook Choi, Zhaoyang Fan, C. Noel Bairey Merz, Prediman K. Shah, Daniel S. Berman, Hyuk-Jae Chang, Debiao Li
Journal: JACC. Cardiovascular imaging (2016)
The Effect of Pre-Transplant Psychological Well-Being on Hematological Reconstitution Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients
Authors: Bilge Bilgin, Mehmet Gunduz, Berker Duman, Ugur Sahin, Hakan Kumbasar, Pervin Topcuoglu, Gunhan Gurman, Meral Beksac
Journal: Blood (2015)
Ongoing professional practice evaluation implementation within STATIT.
Authors: Weiming Shi
Journal: Journal of Clinical Oncology (2012)

283 Background: The OPPE allows the organization to identify professional practice trends that impact quality of care and patient safety. The intent of the standard is that organizations are looking at data on performance for all practitioners with privileges on an ongoing basis, to allow them to take steps to improve performance on a more timely basis. Methods: Infrastructure development. We assigned people for data integration, technical support and metric development. The manager of Clinical Decision Support serve as the administrative coordinator to the program managed the progress of implementation. Leadership Support. To implement the STATIT for OPPE in any hospital, executive leadership support is required to secure funding and resources for the program as well as to support the quality improvement initiatives undertaken that will affect current policies and a wide range of personnel. The early support for the OPPE STATIT came from hospital’s administrative leadership and Performance Improvement leadership. Committed OPPE STATIT implementation team. The basic OPPE STATIT team, consisting of a Manager of Clinical Decision Support, two IT people, and ten Informatics Analysts, requires additional personnel such as departmental Quality Officer with differing expertise for indicator development. Results: All of medical knowledge, patient care activity, and system based indicators plus departmental specific cancer care indicators can be reviewed and any outliers can be drilled down for analysis by division head, department chair and quality officer and signed off on a six-month basis. All individual providers also are able to review his/her performance quality and peers’ comparison. Conclusions: The MIDAS + Statit Physican Profile &amp; Review (PPR) solution is a Web-based system that allows medical providers easy access performance dashboards, which contain up-to-the-moment performance data, annual and interim reviews and drill down to patient level data. The information is necessary to align medical staff with key strategic objectives across the organization. It provides the statistical analysis of patient care quality and safety and opportunities of improvement.
GW26-e2502 Ineffective Communication Leads to Unsatisfactory Sexual Activity among Chinese Patients after Percutaneous Coronary Intervention
Authors: Yuanzhe Jin, Shuo Han, Xiujun Ren, Changlin Han, Meng Wang, Xiaohong Zhang, Fengchen Yao, Zhiying Duan, Yingzi Lin, Jing Liu, Donghui Zhou
Journal: Journal of the American College of Cardiology (2015)